TORONTO, ONTARIO--(Marketwired - June 12, 2017) - Spectral Medical Inc., (TSX:EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced that on June 14, 2017 at 11:30 am EDT (5:30 pm CEST), a special lecture entitled "Critical Care Nephrology Cases Presentation - Results of the EUPHRATES Trial", will be presented by Professor Massimo Antonelli at the 35th annual Vicenza Course on AKI (acute kidney injury) and CRRT(continuous renal replacement therapy) in Vicenza, Italy. The Vicenza Course, organized by Professor Claudio Ronco, is one of the most important and recognized international medical conferences in this field.
The speaker, Professor Massimo Antonelli, is the current Chair of the Department of Anesthesiology and Intensive Care Medicine at the Catholic University of Rome - A. Gemelli University Hospital. He is also the President of the European Society of Intensive Care Medicine (ESICM) and a member of the EUPHRATES trial steering committee.
The lecture will be broadcast live at http://stream6.ondastreaming.eu/ .The webcast will be available free of charge for anyone who wishes to listen, with registration required.
Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.